Effect and safety of quadruple regimen in preventing multi-day cisplatin-based chemotherapy induced nausea and vomiting

doi:10.11958/20231669

Abstract

Abstract:

Objective To evaluate the effectiveness and safety of quadruple regimen in preventing multi-day cisplatin-based chemotherapy-induced nausea and vomiting (CINV). Methods A total of 112 patients with malignant tumors who underwent cisplatin-based chemotherapy. According to the random number table method, patients were divided into the experimental group and the control group, with 56 cases in each group. The control group received cisplatin-based chemotherapy and triple therapy of fosapreitant dimeglumine, ondansetron hydrochloride and dexamethasone tablets. On this basis, the experimental group was given quadruple therapy containing olanzapine tablets. The occurrence of nausea and vomiting, as well as changes in FLIE and HAD scores were observed in both groups. Results The incidence of nausea and vomiting was lower from day 1 (D1) to day 9 (D9) after the beginning of chemotherapy in the experimental group than that in the control group (P<0.05). The incidence of nausea and vomiting in the experimental group was lower than that in the control group. On D9 after the beginning of chemotherapy, the nausea score, vomiting score and total score of FILE were higher in the experimental group than those in the control group (P<0.05). There were no significant differences in depression or anxiety score and incidence of adverse reactions on D1 and D9 after the beginning of chemotherapy between the two groups (P>0.05). Conclusion The quadruple antiemetic regimen can improve the control rate of CINV induced by multi-day cisplatin-based chemotherapy, especially for the control of delayed nausea and vomiting, and improve the quality of life of patients during chemotherapy, with good safety.

Key words: cisplatin, antineoplastic combined chemotherapy protocols, nausea, vomiting, drug evaluation

CLC Number:

R730.53

Figures/Tables 5

References 19

[1]	马治, 王欣爽, 刘玥, 等. 甘草次酸的差向异构体对顺铂诱导H9c2心肌细胞损伤的保护机制[J]. 天津医药, 2022, 50(12):1264-1269.
	MA Z, WANG X S, LIU Y, et al. The protective mechanism of differential isomers of glycyrrhetinic acid on cisplatin-induced H9c2 cardiomyocyte injury[J]. Tianjin Med J, 2022, 50(12):1264-1269. doi:10.11958/20220987.
[2]	GUO Q, ZHANG T, GONG Y, et al. Aldehyde dehydrogenase 6 family member A1 negatively regulates cell growth and to cisplatin sensitivity in bladder cancer[J]. Mol Carcinog, 2022, 61(7):690-701. doi:10.1002/mc.23411.
[3]	GABBY M E, BUGIN K, LYONS E. Review article:the evolution of endpoint assessments for chemotherapy-induced nausea and vomiting and post-operative nausea and vomiting—a perspective from the US Food and Drug Administration[J]. Aliment Pharmacol Ther, 2021, 54(1):7-13. doi:10.1111/apt.16386.
[4]	AAPRO M, SCOTTÉ F, ESCOBAR Y, et al. Practice patterns for prevention of chemotherapy-induced aausea and vomiting and antiemetic guideline adherence based on real-world prescribing data[J]. Oncologist, 2021, 26(6):e1073-e1082. doi:10.1002/onco.13716.
[5]	KARAM J A, PULIGANDLA M, FLAHERTY K T, et al. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma:post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805[J]. BJU Int, 2022, 129(6):718-722. doi:10.1111/bju.15587.
[6]	ALYAMI M, KIM B J, VILLENEUVE L, et al. Ninety-day post-operative morbidity and mortality using the National Cancer Institute's common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. Int J Hyperthermia, 2018, 34(5):532-537. doi:10.1080/02656736.2017.1367846.
[7]	LUA P L, SALIHAH N, MAZLAN N. Effects of inhaled ginger aromatherapy on chemotherapy-induced nausea and vomiting and health-related quality of life in women with breast cancer[J]. Complement Ther Med, 2015, 23(3):396-404. doi:10.1016/j.ctim.2015.03.009.
[8]	PARK J H, RHEE S M, KIM H S, et al. Effects of anxiety and depression measured via the hospital anxiety and depression scale on early pain and range of motion after rotator cuff repair[J]. Am J Sports Med, 2021, 49(2):314-320. doi:10.1177/0363546520976574.
[9]	GAO A, GUAN S, SUN Y, et al. Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV)in patients receiving highly emetogenic chemotherapy[J]. BMC Cancer, 2023, 23(1):609. doi:10.1186/s12885-023-11070-3.
[10]	MUKHOPADHYAY S, DUTTA P, BANERJEE S, et al. Low-dose olanzapine,sedation and chemotherapy-induced nausea and vomiting:a prospective randomized controlled study[J]. Future Oncol, 2021, 17(16):2041-2056. doi:10.2217/fon-2020-0834.
[11]	HERRSTEDT J, ROILA F, WARR D, et al. 2016 Updated MASCC/ESMO consensus recommendations:prevention of nausea and vomiting following high emetic risk chemotherapy[J]. Support Care Cancer,2017, 25(1):277-288. doi:10.1007/s00520-016-3313-0.
[12]	HESKETH P J, KRIS M G, BASCH E, et al. Antiemetics:American society of clinical oncology clinical practice guideline update[J]. J Clin Oncol, 2017, 35(28):3240-3261. doi:10.1200/JCO.2017.74.4789.
[13]	中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会. 中国肿瘤药物治疗相关恶心呕吐防治专家共识(2022年版)[J]. 中华医学杂志, 2022, 102(39):3080-3094.
	China anti-cancer association tumor clinical chemotherapy professional committee, China anti-cancer association tumor support therapy professional committee. Chinese experts’consensus on the prevention and treatment of nausea and vomiting related to anti-cancer drug treatment(2022 version)[J]. Natl Med J China, 2022, 102(39):3080-3094. doi:10.3760/cma.j.cn112137-20220810-01724.
[14]	QIN L, ZHAN Z, WEI C, et al. Hsa-circRNA-G004213 promotes cisplatin sensitivity by regulating miR-513b-5p/PRPF39 in liver cancer[J]. Mol Med Rep, 2021, 23(6):421. doi:10.3892/mmr.2021.12060.
[15]	OHATA K, FUJII H, SADAKA S, et al. Comparison of chemotherapy-induced nausea and vomiting between gemcitabine plus nabpaclitaxel combination chemotherapy and gemcitabine monotherapy in patients with advanced pancreatic cancer[J]. Anticancer Res, 2021, 41(7):3643-3648. doi:10.21873/anticanres.15154.
[16]	PATEL P, ROBINSON P D, DEVINE K A, et al. Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients:clinical practice guideline update[J]. Pediatr Blood Cancer, 2021, 68(5):e28947. doi:10.1002/pbc.28947.
[17]	NAVARI R M, GRAY S E, KERR A C. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting:a randomized phase III trial[J]. J Support Oncol, 2011, 9(5):188-195. doi:10.1016/j.suponc.2011.05.002.
[18]	于韦韦, 曲范杰, 张倩馨, 等. 奥氮平联合地塞米松治疗阿片类药物胃肠道反应的临床疗效观察[J]. 实用医院临床杂志, 2022, 19(2):96-99.
	YU W W, QU F J, ZHANG Q X, et al. Clinical observation of olanzapine combined with dexamethasone in the treatment of gastrointestinal reaction of opioid[J]. Pract J Clin Med, 2022, 19(2):96-99. doi:10.3969/j.issn.1672-6170.2022.02.027.
[19]	MAEDA I, SATOMI E, KIUCHI D, et al. Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams:a multicenter prospective observational study[J]. Support Care Cancer, 2021, 29(10):5831-5838. doi:10.1007/s00520-021-06067-2.

组别	n		年龄/岁		男性		合并晕动症	既往孕期有妊娠反应史
对照组	56		54.80±9.21		31（55.36）		8（14.29）	11（44.00）
试验组	56		56.13±9.78		29（51.79）		11（19.64）	14（51.85）
t或χ²			0.736		0.144		0.570	0.321
组别		饮酒史		吸烟史		化疗呕吐史			首次化疗
对照组		29（51.79）		36（64.29）		11（64.71）			39（69.64）
试验组		27（48.21）		39（69.64）		8（61.54）			43（76.79）
χ²		0.143		0.363		0.032			0.728

组别	n		年龄/岁		男性		合并晕动症	既往孕期有妊娠反应史
对照组	56		54.80±9.21		31（55.36）		8（14.29）	11（44.00）
试验组	56		56.13±9.78		29（51.79）		11（19.64）	14（51.85）
t或χ²			0.736		0.144		0.570	0.321
组别		饮酒史		吸烟史		化疗呕吐史			首次化疗
对照组		29（51.79）		36（64.29）		11（64.71）			39（69.64）
试验组		27（48.21）		39（69.64）		8（61.54）			43（76.79）
χ²		0.143		0.363		0.032			0.728

组别	n		恶心		急性期恶心		延迟期恶心
对照组	56		45（80.36）		17（30.36）		45（80.36）
试验组	56		30（53.57）		10（17.86）		28（50.00）
χ²			9.081^＊＊		2.391		11.369^＊＊
组别		呕吐		急性期呕吐		延迟期呕吐
对照组		29（51.79）		9（16.07）		29（51.79）
试验组		16（28.57）		5（8.93）		13（23.21）
χ²		6.278^＊		1.306		9.752^＊＊

组别	n		恶心		急性期恶心		延迟期恶心
对照组	56		45（80.36）		17（30.36）		45（80.36）
试验组	56		30（53.57）		10（17.86）		28（50.00）
χ²			9.081^＊＊		2.391		11.369^＊＊
组别		呕吐		急性期呕吐		延迟期呕吐
对照组		29（51.79）		9（16.07）		29（51.79）
试验组		16（28.57）		5（8.93）		13（23.21）
χ²		6.278^＊		1.306		9.752^＊＊

组别		恶心
组别		D1	D9		t
对照组		51.93±7.41	40.86±7.70		8.774^＊＊
试验组		51.73±6.38	46.54±6.81		4.481^＊＊
t		0.150	4.134^＊＊
组别		呕吐
组别		D1	D9		t
对照组		52.41±6.71	46.59±8.49		4.777^＊＊
试验组		53.09±5.92	49.57±7.07		3.246^＊＊
t		0.567	2.020^＊
组别	总分
组别	D1			D9		t
对照组	104.34±12.38			87.45±13.13		8.330^＊＊
试验组	104.82±9.10			96.11±10.91		6.002^＊＊
t	0.235			3.798^＊＊